NeuroSense Therapeutics Ltd. Warrant

NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for neurodegenerative diseases in the United States and internationally. Its lead product, PrimeC, is an extended-release oral fixed-dose combination of ciprofloxacin and celecoxib. PrimeC is in Phase 2b/3 trials for amyotrophic lateral sclerosis, has completed Phase 2 trials for Alzheimer's, and is in preclinical studies for Parkinson's disease. The preclinical pipeline also includes StabiliC for Parkinson's disease and CogniC for Alzheimer's disease. Incorporated in 2017, the company is headquartered in Herzliya, Israel.